China's AIM jumps on vaccine's clinical trial application in US

AIM Vaccine

05/02/2025 02:58

** AIM Vaccine  6660.HK  soars as much as 10.1% to HK$6.09;
on course for biggest one-day pct gain since Nov. 1, 2024
    ** Stock hits highest since Jan. 2 on second consecutive
session of gains
    ** Co submits application for clinical trial of mRNA RSV
(respiratory syncytial virus) vaccines to U.S. FDA
    ** Says preclinical animal tests results showed that humoral
and cellular immunity of its mRNA RSV vaccine significantly
higher than those of internationally marketed products
    ** Adds industry consultant expects RSV vaccines' global
market size to reach $16.7 bln by 2030 from $2.46 bln in 2023
    ** RSV is a common respiratory tract infection pathogen,
which is highly contagious and widely prevalent
    ** Stock fell 21.8% last year

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))